08/12/2013 - 8:53am

Teva Pharmaceutical and Perrigo Co. announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country.

08/12/2013 - 8:43am

Perrigo Co. announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Body Oil.

08/09/2013 - 1:34pm

The National Association of Specialty Pharmacy will include a presentation of research posters at its inaugural Strategic Business Exchange in the fall, the group said.

08/09/2013 - 12:44pm

Actavis and Warner Chilcott have received approval from all necessary antitrust clearances for their merger from regulators outside the United States, the companies said.

08/09/2013 - 11:56am

As pharmacy evolves from medication dispensing to a key component of the healthcare system, strengthening the pharmacist's role in health care was the dominant theme at a recent conference sponsored by a coalition of pharmacy groups.

08/09/2013 - 11:46am

VoicePort announced the launch of its Medication Synchronization automated solution with two U. S. pharmacy chain clients and are in final stage negotiations with several others in support of helping pharmacies deliver increased patient health-and-wellness.

08/09/2013 - 9:00am

As part of its continued commitment to supporting future pharmacists, Cardinal Health announced that six pharmacy schools across the country will receive more than $625,000 in funding through the Cardinal Health Pharmacy Scholarship Program.

08/08/2013 - 4:04pm

Of all the policies to come out of the Obama administration, few have caused more controversy and greater uncertainty than healthcare reform.

08/08/2013 - 4:04pm

The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.